drugset

drugset / Trial / NCT03760614

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

NCT03760614 ↗

Phase 1 Withdrawn Abramson Cancer Center at Penn Medicine Syndax Pharmaceuticals · collab

NaSequentialOpen-labelTreatment

Summary

The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.

Timeline

Start: 2021-01
Primary completion: 2022-07
Completion: 2022-11

Publications

Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibanez-Costa A, Dubrot J, Earl J, Melian EB, Kataki A, Kolnikova G, Madjarov G, Chaushevska M, Strnadel J, Tanic M, Tomas M, Dubovan P, Urbanova M, Buocikova V, Smolkova B. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Semin Cancer Biol. 2025 Feb;109:101-124. doi: 10.1016/j.semcancer.2025.01.003. Epub 2025 Jan 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Entinostat	Small molecule	2 mg	Oral
Subject	Entinostat	Small molecule	3 mg	Oral
Subject	Entinostat	Small molecule	4 mg	Oral
Subject	Entinostat	Small molecule	5 mg	Oral

Indications